Key result
Cardiac rehab links to a ~1.2 kg/m2 greater BMI reduction in obese versus non-obese CAD patients.
Why the study?
Up to 80% of patients referred to cardiac rehabilitation are overweight or obese, but the comparative effects of phase 2 cardiac rehabilitation in obese versus non-obese patients after total revascularization were unclear.
Does a 12-week phase 2 cardiac rehabilitation program improve cardiovascular risk factors and exercise capacity differently in obese versus non-obese patients with stable coronary artery disease?
Cohort (n=120)
No
Does a 12-week phase 2 cardiac rehabilitation program improve cardiovascular risk factors and exercise capacity differently in obese versus non-obese patients with stable coronary artery disease?
Absolute Event Rate: -1.78% vs -0.6%
p-value: p=<0.001
A 12-week phase 2 cardiac rehabilitation program provides greater reductions in BMI, blood pressure, and LDL-C in obese patients compared to non-obese patients with stable coronary artery disease, while equally improving exercise capacity in both groups.
May support targeted cardiac rehabilitation for obese stable CAD patients; leaves open confirmation in randomized trials.
Background Obesity is associated with significant cardiovascular morbidity and mortality effects. Cardiac rehabilitation programs cause a significant reduction in cardiovascular mortality and a reduction in all cardiovascular risk factors. Up to 80% of patients referred to cardiac rehabilitation programs are either overweight or obese. This study aimed to compare the effects of a phase 2 cardiac rehabilitation program on obese and non-obese patients with stable coronary artery disease following total revascularization by coronary angioplasty. Results This was a prospective study including 120 patients with stable coronary artery disease. Patients were enrolled in a 12-week phase 2 cardiac rehabilitation program. Patients were classified into two groups based on their body mass index (BMI): those with a BMI < 30 kg/m 2 were considered non-obese ( n = 58) while those with a BMI ≥ 30 kg/m 2 were considered obese ( n = 62). At baseline, BMI and blood pressure (BP) were recorded; fasting blood sugar, triglyceride levels, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels were assessed; and echocardiography was used to measure left ventricular ejection fraction (LVEF). These were re-assessed after completion of the program. At baseline, there were more females in the obese group 20 (32.25%) vs 6 (10.13%) ( p = 0.04), more hypertensives ( p = 0.023), and less smokers 32 (51%) vs 46 (79%) ( p = 0.025). Obese patients achieved fewer metabolic equivalent of tasks (METs) 7.97 ± 2.4 vs 9.74 ± 2.47 ( p = 0.007) and had higher LDL-C levels 121.63 ± 36.52 mg/dl vs 95.73 ± 31.51 mg/dl ( p = 0.005). At the end of the program, obese patients showed more reduction in BMI − 1.78 ± 1.46 kg/m 2 vs − 0. 60 ± 0.70 kg/m 2 ( p < 0.001) and systolic and diastolic BP ( p = 0.016 and 0.038, respectively). LDL-C level was more reduced in the obese group − 25.76 ± 14.19 mg/dl vs − 17.37 ± 13.28 mg/dl ( p = 0.022). Non-obese patients had more increase in LVEF ( p = 0.024). There was no difference between obese and non-obese patients in the magnitude of increase in METs achieved ( p = 0.21). Conclusion Cardiac rehabilitation programs lead to an improvement in cardiovascular disease risk factors with more reduction in BMI, BP, and LDL-C levels in obese patients compared to non-obese ones. LVEF was more increased in non-obese individuals. Exercise capacity in the form of METs achieved was equally improved in both groups.
No takes yet. Share an insight, caveat, or question.
Missiri et al. (2021) conducted a cohort in Stable coronary artery disease (n=120). Phase 2 cardiac rehabilitation program vs. Non-obese patients (BMI < 30 kg/m2) was evaluated on Change in BMI (kg/m2) (p=<0.001). A 12-week phase 2 cardiac rehabilitation program led to a greater reduction in BMI (-1.78 vs -0.60 kg/m2, p<0.001) in obese patients compared to non-obese patients with stable coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: